Compare DRDB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRDB | LRMR |
|---|---|---|
| Founded | 2024 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 332.1M |
| IPO Year | 2024 | N/A |
| Metric | DRDB | LRMR |
|---|---|---|
| Price | $10.42 | $3.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 57.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $595.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.61 |
| 52 Week High | $10.47 | $6.91 |
| Indicator | DRDB | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 56.10 |
| Support Level | $10.43 | $3.12 |
| Resistance Level | $10.47 | $3.69 |
| Average True Range (ATR) | 0.01 | 0.26 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 9.09 | 97.51 |
Roman DBDR Acquisition Corp II is a blank check company.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.